Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Surging SciClone Pharmaceuticals (SCLN), Up By 14.66% Today?

SciClone Pharmaceuticals Inc (NASDAQ:SCLN) is a $503.65 million market cap company which serves as a provider of therapies for oncology, infectious diseases and cardiovascular disorders in China, Hong Kong and the US. So far this year, the stock of the company has appreciated by a stout 28.20%, while during today’s trading session alone the shares have gained over 14.50%, as they are changing hands like a hot potato. The large increase in trading volume and bullish charge of the shares seems to largely be based on a bullish call from an analyst. Yesterday, analysts at MLV & Co initiated coverage on the stock with a ‘Buy’ rating and a $15 target, which suggested potential upside of well over 60% at that time. Since there was no other major news announced over the past two days that could have triggered such a jump, let’s briefly describe the recent performance of the company as well as the activity of insiders and hedge fund managers. In the company’s last earnings report, SciClone Pharmaceuticals Inc (NASDAQ:SCLN) surprised investors with 26.4% year-over-year revenue growth versus the 1.9% industry average. The EPS growth was even more striking, a 112.5% increase from the previous year’s quarter. The company is financially sound, having no debt and a quick ratio of 6.82.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

SciClone Pharmaceuticals Inc (NASDAQ:SCLN) investors should pay attention to an increase in enthusiasm from smart money of late. The company was in 16 hedge funds’ portfolios, with their holdings totaling $40.08 million in value at the end of March, while there were 15 hedge funds in our database holding around $33.40 million of the stock at the end of the previous quarter.

We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 142%, nearly 2.5 times greater returns than the S&P 500 during the same period (see more details).

At the moment there are tons of signals market participants use to assess their stock investments. A pair of the best signals are hedge fund and insider trading activity. Experts at Insider Monkey, a website specializing in hedge funds, have shown that, historically, those who follow the best picks of the top money managers can outpace their index-focused peers by a solid amount (see the details here). In terms of insider activity, according to a Form 4 filing on June 29, the top executives own 0.6% of shares of the company. During the last three months alone, there were 262,140 shares offloaded, with Friedhelm Blobel, the CEO, heading the list of sellers with around 120,000 shares sold.

Let’s next take a look at the detailed hedge fund activity in SciClone Pharmaceuticals.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.